A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Exploratory Dose-response Study to Assess the Efficacy and Safety of Different Oral Doses of BAY1128688 in Women With Symptomatic Endometriosis Over a 12-week Treatment Period
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs BAY 1128688 (Primary)
- Indications Endometriosis; Pelvic pain
- Focus Therapeutic Use
- Acronyms AKRENDO1
- Sponsors Bayer
- 29 Nov 2018 Status changed from active, no longer recruiting to discontinued.
- 22 Nov 2018 This trial was discontinued in Czech Republic (end date: 2018-10-22), according to European Clinical Trials Database.
- 06 Nov 2018 This trial has been discontinued in Denmark/